SCHEMBL10043691

SCHEMBL10043691

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3cc(C)on3)ccc1C)c(=O)n2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
ALDH1A1 P00352 4/20 0.48
TP53 P04637 2/20 0.48
GLA P06280 1/20 0.48
HTT P42858 1/20 0.48
MAPT P10636 4/20 0.44
SYK P43405 1/20 0.43
KDM6B O15054 1/20 0.43
KDM5A P29375 1/20 0.43
KDM4D Q6B0I6 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
HIF1AN Q9NWT6 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
KDM3A Q9Y4C1 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043870 0.93 RAB9A (0.40) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL10043697 0.88 SYK (0.43) NPC1RAB9AMAPTSYKRAF1
SCHEMBL10043960 0.86 SYK (0.43) NPC1RAB9AALDH1A1MAPTSYK
SCHEMBL10043679 0.86 SYK (0.47) NPC1RAB9AMAPTSYKSMN1; SMN2
SCHEMBL10043746 0.86 GRM4 (0.48) NPC1RAB9AMAPTSYKSMN1; SMN2
SCHEMBL10043744 0.86 SYK (0.44) NPC1RAB9AALDH1A1SYKSMN1; SMN2
SCHEMBL10043707 0.85 SYK (0.43) NPC1RAB9AMAPTSYKSMN1; SMN2
SCHEMBL10043745 0.85 SYK (0.45) NPC1RAB9AALDH1A1TP53MAPT
SCHEMBL10043705 0.84 MAPT (0.54) NPC1RAB9AALDH1A1TP53MAPT
SCHEMBL10043706 0.84 GRM1 (0.46) NPC1RAB9AMAPTSYKRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC NPC1 4095/4885RAB9A 1818/4885ALDH1A1 4274/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC NPC1 4095/4885RAB9A 1818/4885ALDH1A1 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.